Saturday, November 21, 2026
Financial News
Sep 22, 2026, 3:46 PMBiotechnology

Viking Therapeutics Stock Soars as Monthly VK2735 Dosing Maintains Weight Loss

Viking Therapeutics’ VK2735 maintained weight loss in a clinical trial, including with monthly dosing, as it targets Eli Lilly’s Zepbound in the market.

A measuring-tape bridge supported by a medicine droplet links monthly dosing with sustained weight loss.
Listen to this briefingAudio briefing

Summary

MarketWatch reported on September 22, 2026, that Viking Therapeutics’ investigational VK2735 helped clinical-trial participants maintain weight loss, including those receiving the drug once monthly. VK2735 targets both GLP-1 and GIP and is being developed to compete with Eli Lilly’s Zepbound.

Viking Therapeutics shares were soaring, although the limited feed summary provided no stock-price move, trial phase, participant count, efficacy measurements, safety results, dosing details beyond once-monthly use, or development timeline.

Positives

  • VK2735 helped clinical-trial participants maintain their weight loss, according to MarketWatch.
  • Once-monthly VK2735 recipients also maintained weight loss, extending the reported result to a less frequent dosing schedule.
  • VK2735 targets both GLP-1 and GIP and is being developed as a potential Zepbound competitor.
  • Viking Therapeutics stock was soaring when MarketWatch published the report.

Risks & concerns

  • VK2735 remains in development, and the available summary does not report an approval or commercialization timeline.
  • The limited feed disclosed no trial phase, participant count, efficacy measurements, statistical results, or safety findings.
  • Eli Lilly’s Zepbound is the named competing drug, placing VK2735 against an established rival.
  • The report quantified neither Viking Therapeutics’ share-price increase nor the clinical result’s magnitude.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/this-glp-1-drug-helped-people-maintain-their-weight-loss-in-a-clinical-trial-even-for-those-taking-it-once-a-month-f70929b5?mod=mw_rss_topstories
Read full article
Editorial note: Financial News summarizes and analyzes third-party reporting and public filings. The source link is the authoritative document. This page does not reproduce the full source text and is not investment advice.

More From The Wire

A vaccine vial rocket rises from a financial chart toward a cloud shaped like dividing cells. BiotechnologyNov 6

Moderna Stock Jumps on 25% 2026 Growth Outlook, Cancer Vaccine in Focus

A glowing medicine capsule rockets through a pancreas-shaped barrier, symbolizing unexpectedly strong launch sales. BiotechnologyNov 5

Revolution Medicines Pancreatic Cancer Drug Launch Beats Sales Expectations

A DNA-shaped balloon deflates near a finish line, symbolizing cooling hopes for Moderna’s cancer vaccine. BiotechnologyOct 26

Moderna Cancer Vaccine Enthusiasm Cools Amid High Phase 3 Expectations